Myopia-26, the female-limited form of early-onset high myopia, occurring in a European family.

ARR3 Early onset high myopia G-protein coupled receptor Intrinsically photosensitive retinal ganglion cell Mendelian inheritance Monogenic disorder X-arrestin X-linked female-limited high myopia

Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
22 01 2021
Historique:
received: 16 05 2020
accepted: 05 01 2021
entrez: 23 1 2021
pubmed: 24 1 2021
medline: 22 6 2021
Statut: epublish

Résumé

Female-limited early-onset high myopia, also called Myopia-26 is a rare monogenic disorder characterized by severe short sightedness starting in early childhood and progressing to blindness potentially by the middle ages. Despite the X-linked locus of the mutated ARR3 gene, the disease paradoxically affects females only, with males being asymptomatic carriers. Previously, this disease has only been observed in Asian families and has not gone through detailed investigation concerning collateral symptoms or pathogenesis. We found a large Hungarian family displaying female-limited early-onset high myopia. Whole exome sequencing of two individuals identified a novel nonsense mutation (c.214C>T, p.Arg72*) in the ARR3 gene. We carried out basic ophthalmological testing for 18 family members, as well as detailed ophthalmological examination (intraocular pressure, axial length, fundus appearance, optical coherence tomography, visual field- testing) as well as colour vision- and electrophysiology tests (standard and multifocal electroretinography, pattern electroretinography and visual evoked potentials) for eight individuals. Ophthalmological examinations did not reveal any signs of cone dystrophy as opposed to animal models. Electrophysiology and colour vision tests similarly did not evidence a general cone system alteration, rather a central macular dysfunction affecting both the inner and outer (postreceptoral and receptoral) retinal structures in all patients with ARR3 mutation. This is the first description of a Caucasian family displaying Myopia-26. We present two hypotheses that could potentially explain the pathomechanism of this disease.

Sections du résumé

BACKGROUND
Female-limited early-onset high myopia, also called Myopia-26 is a rare monogenic disorder characterized by severe short sightedness starting in early childhood and progressing to blindness potentially by the middle ages. Despite the X-linked locus of the mutated ARR3 gene, the disease paradoxically affects females only, with males being asymptomatic carriers. Previously, this disease has only been observed in Asian families and has not gone through detailed investigation concerning collateral symptoms or pathogenesis.
RESULTS
We found a large Hungarian family displaying female-limited early-onset high myopia. Whole exome sequencing of two individuals identified a novel nonsense mutation (c.214C>T, p.Arg72*) in the ARR3 gene. We carried out basic ophthalmological testing for 18 family members, as well as detailed ophthalmological examination (intraocular pressure, axial length, fundus appearance, optical coherence tomography, visual field- testing) as well as colour vision- and electrophysiology tests (standard and multifocal electroretinography, pattern electroretinography and visual evoked potentials) for eight individuals. Ophthalmological examinations did not reveal any signs of cone dystrophy as opposed to animal models. Electrophysiology and colour vision tests similarly did not evidence a general cone system alteration, rather a central macular dysfunction affecting both the inner and outer (postreceptoral and receptoral) retinal structures in all patients with ARR3 mutation.
CONCLUSIONS
This is the first description of a Caucasian family displaying Myopia-26. We present two hypotheses that could potentially explain the pathomechanism of this disease.

Identifiants

pubmed: 33482870
doi: 10.1186/s13023-021-01673-z
pii: 10.1186/s13023-021-01673-z
pmc: PMC7825233
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

45

Subventions

Organisme : Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
ID : K119298
Organisme : Gazdaságfejlesztési és Innovációs Operatív Program (HU)
ID : GINOP-2.3.2-15-2016-00001

Références

Prog Retin Eye Res. 2013 Jan;32:64-87
pubmed: 22986412
Nat Genet. 2018 Jun;50(6):834-848
pubmed: 29808027
Vision Res. 1999 Apr;39(8):1415-35
pubmed: 10343811
J Neurosci. 2005 Jun 1;25(22):5438-45
pubmed: 15930394
J Neurosci. 2015 Dec 2;35(48):15955-70
pubmed: 26631476
Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4413-4424
pubmed: 30193312
Optom Vis Sci. 2016 Sep;93(9):1061-3
pubmed: 27415440
Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M31-M88
pubmed: 30817827
Doc Ophthalmol. 2013 Feb;126(1):1-7
pubmed: 23073702
Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M89-M105
pubmed: 30817828
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5407-16
pubmed: 26284544
Optom Vis Sci. 2009 Feb;86(2):76-8
pubmed: 19156003
Neuron. 2010 Jul 15;67(1):49-60
pubmed: 20624591
Handb Exp Pharmacol. 2014;219:117-31
pubmed: 24292827
Neuron. 2008 Aug 14;59(3):462-74
pubmed: 18701071
Doc Ophthalmol. 2020 Apr;140(2):95-101
pubmed: 31749034
J Med Genet. 2000 Mar;37(3):227-31
pubmed: 10777361
Doc Ophthalmol. 2015 Feb;130(1):1-12
pubmed: 25502644
Vision Res. 2006 Oct;46(19):3079-89
pubmed: 16782165
Exp Eye Res. 2019 Nov;188:107778
pubmed: 31472110
Front Endocrinol (Lausanne). 2018 Mar 02;9:66
pubmed: 29551993
J Histochem Cytochem. 1992 Mar;40(3):343-52
pubmed: 1372630
Ophthalmic Physiol Opt. 2017 Sep;37(5):557-567
pubmed: 28721695
Doc Ophthalmol. 2018 Jun;136(3):199-206
pubmed: 29934802
J Pineal Res. 2001 Sep;31(2):145-54
pubmed: 11555170
PLoS One. 2019 Jun 18;14(6):e0217111
pubmed: 31211778
Ophthalmology. 2016 May;123(5):1036-42
pubmed: 26875007
Ophthalmic Physiol Opt. 2018 May;38(3):217-245
pubmed: 29691928
Trends Neurosci. 2003 Jun;26(6):314-20
pubmed: 12798601
Physiol Rev. 2010 Oct;90(4):1547-81
pubmed: 20959623
Doc Ophthalmol. 2010 Feb;120(1):111-9
pubmed: 19826847
Mol Vis. 2016 Oct 26;22:1257-1266
pubmed: 27829781
Vision Res. 1995 May;35(9):1175-94
pubmed: 7610579
Invest Ophthalmol Vis Sci. 2015 Sep;56(10):6121-31
pubmed: 26393671
Am J Clin Nutr. 2016 Apr;103(4):1135-44
pubmed: 26961928
Curr Biol. 2007 Dec 18;17(24):2122-8
pubmed: 18082405
Prog Mol Biol Transl Sci. 2013;118:243-65
pubmed: 23764057
Doc Ophthalmol. 2012 Feb;124(1):1-13
pubmed: 22038576
Eur J Pharmacol. 1984 Oct 1;105(1-2):193-4
pubmed: 6489448
Front Neurol. 2018 Nov 27;9:941
pubmed: 30538662
J Physiol. 2004 Jan 15;554(Pt 2):467-82
pubmed: 14565990
J Clin Endocrinol Metab. 2003 Sep;88(9):4502-5
pubmed: 12970330
Am J Ophthalmol. 2015 May;159(5):877-83.e7
pubmed: 25634530

Auteurs

Noémi Széll (N)

Kenézy Gyula University Hospital, Debrecen Medical University, Debrecen, Hungary.
Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary.

Tamás Fehér (T)

Institute of Biochemistry, Biological Research Centre, Szeged, Hungary. feher.tamas@brc.hu.

Zoltán Maróti (Z)

Genetic Diagnostic Laboratory, University of Szeged, Szeged, Hungary.

Tibor Kalmár (T)

Genetic Diagnostic Laboratory, University of Szeged, Szeged, Hungary.

Dóra Latinovics (D)

Seqomics Biotechnology Ltd, Mórahalom, Hungary.

István Nagy (I)

Institute of Biochemistry, Biological Research Centre, Szeged, Hungary.
Seqomics Biotechnology Ltd, Mórahalom, Hungary.

Zsuzsanna Z Orosz (ZZ)

Department of Ophthalmology, Faculty of Medicine, University of Szeged, Szeged, Hungary.

Márta Janáky (M)

Department of Ophthalmology, Faculty of Medicine, University of Szeged, Szeged, Hungary.

Andrea Facskó (A)

Department of Ophthalmology, Faculty of Medicine, University of Szeged, Szeged, Hungary.

Zoltán Sohajda (Z)

Kenézy Gyula University Hospital, Debrecen Medical University, Debrecen, Hungary. zoltansohajda@hotmail.com.
Department of Ophthalmology, Faculty of Medicine, University of Szeged, Szeged, Hungary. zoltansohajda@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH